{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-096536","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.421717+00:00","generated_at":"2026-06-07T11:11:46.116763+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Oramed appoints Dr. Daniel Aghion to board of directors effective Jan 1, 2024","bullets":["Board size increased by one; Dr. Aghion fills resulting vacancy effective January 1, 2024.","Aghion is a neurosurgeon at Memorial Neuroscience Institute since 2016.","Compensation will match fees paid to other non-executive directors.","No arrangements or transactions requiring disclosure under Item 404(a) in connection with appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-096536","json":"https://secwatch.observer/filing/0001213900-23-096536.json","markdown":"https://secwatch.observer/filing/0001213900-23-096536.md","text":"https://secwatch.observer/filing/0001213900-23-096536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023096536/0001213900-23-096536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023096536/ea190226-8k_oramedpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:11:46.116763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5300ea4b36","claim":"Dr. Daniel Aghion was appointed as director at ORAMED PHARMACEUTICALS INC..","evidence_excerpt":"On December 18, 2023, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Dr. Daniel Aghion to serve as a director to fill the resulting vacancy, effective as of January 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023096536/0001213900-23-096536-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}